
MTB · NYSE
The consensus is Hold from 20 analysts, with the supplied central target at $255 versus the $253.06 closing price. Available target data are inconsistent: StockAnalysis reports a $238.64 average, Benzinga cites $235 across RBC Capital, JPMorgan, and Cantor Fitzgerald, Public reports $251.91, and Zacks gives a $200-to-$269 range. Truist is the most bullish named firm in the evidence at $268; the least bullish named firm cannot be identified because the lower published targets are not attributed individually. Revisions were mixed rather than uniformly positive: Truist raised its target from $230, while Deutsche Bank downgraded the rating from Buy to Hold. The substantive disagreement is whether improved reported earnings justify a higher valuation despite limited consensus upside.